SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending after reporting quarterly results that beat analyst expectations, fueling massive investor optimism regarding its AI-driven turnaround and server processor demand. The community is actively discussing a significant short squeeze, with many retail investors highlighting their long-term conviction and celebrating the stock's surge to record highs.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is surging in after-hours trading, fueled by a sympathy rally following Intel's stronger-than-expected earnings and guidance which highlighted a major rebound in AI-driven data center CPU demand. The community is actively debating whether this momentum marks a sustainable phase of expansion or a blow-off top, with bullish investors pointing to the growing AI infrastructure cycle as justification for higher price targets while bears express concern over the stock's rapid valuation increase and overbought technical indicators.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing intense volatility and community-driven buying pressure following a major legal victory where a jury awarded the company substantial damages against a rival for fraudulent bot usage. Investors are actively debating whether the stock will trigger a massive short squeeze given the potential for a billion-dollar judgment and limited float, leading to aggressive accumulation despite frequent trading halts.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in SOXS are facing significant frustration as the semiconductor sector continues an unprecedented parabolic rally, leading many to label the persistent lack of red days in the underlying index as market manipulation. Community discussion is dominated by severe losses from volatility decay, debates over whether to capitulate or average down, and intense focus on upcoming semiconductor earnings as the potential catalyst for a long-awaited mean reversion.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to a significant multi-billion dollar AI-driven drug discovery partnership with Insilico Medicine, while market participants closely monitor the upcoming FDA decision for its oral GLP-1 weight-loss drug, Foundayo. The community is actively debating the competitive landscape between Lilly and Novo Nordisk, weighing pipeline diversification against potential regulatory and pricing pressures in the broader pharma sector.

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics is experiencing extreme volatility and massive trading volume following the lifting of a quotation resumption halt after its recent IPO. Market participants are intensely focused on the stock's price action and liquidity as they monitor the name for potential base-building or signs of a sharp reversal.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors react to the company's confirmed commercial orders from Marvell Technology and its strategic shift to U.S.-based operations. The community is heavily focused on the company's emergence as a vital component in AI data center infrastructure, with traders debating whether this surge represents a sustainable valuation re-rating or a short-lived gamma squeeze triggered by heavy call option activity.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a community-driven meme project that encourages a high-risk, "no-roadmap" investment philosophy aimed at rapid growth. Investors are actively discussing the token's low market cap and the developer's frequent airdrops, while rallying to push the asset through its bonding curve and onto major tracking platforms.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently the focal point of intense community speculation and volatility as it continues a record-breaking rally, with investors debating whether this momentum represents a sustainable super-cycle or a classic blow-off top. The conversation is dominated by contrasting views on the sustainability of semiconductor demand, with many traders riding the parabolic momentum while others aggressively hedge with inverse funds in anticipation of a potential market reversal.

ASGN Incorporated engages in the provision of information technology services and solutions. It operates through the Commercial and Federal Government segments. The Commercial segment involves the provision of consulting, creative digital marketing, and permanent placement services. The Federal Government segment provides mission-critical solutions. The company was founded on December 30, 1985 and is headquartered in Glen Allen, VA.

ASGN Inc

ASGN is experiencing heightened volatility and intense social media discussion as investors debate a significant corporate rebrand to 'EFOR' alongside concerns over institutional short selling and potential overreaction to recent financial performance. Market participants are actively comparing the company's valuation against its fundamental health, leading to a polarized community split between those viewing the price drop as a deep-value opportunity and others warning of ongoing downward pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data

Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.

Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?

Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports...

Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7% - Time to Buy?

Kura Oncology (NASDAQ:KURA) Trading Up 9.7% - Here's What Happened...

Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results

Kura Oncology says kidney cancer trial data shows 44% response rate and strong disease control; analysts maintain Buy ratings.read more...

<ul class="summary-bullets"><li>The treatment showed an objective response rate of 44% and a disease control rate of 94%.</li><li>Kura said tumor shrinkage was seen in 75% of the 16 patients on trial.</li><li>The results were presented at the International Kidney Cancer Symposium Europe 2026 in Paris.</li></ul>Shares of Kura Oncology (KURA) jumped more than 13% in pre-market trading on Friday after the clinical-stage biotech firm reported encouraging early data from its ongoing trial for the treatment of advanced kidney cancer.The results, presented at the International Kidney Cancer Symposium Europe 2026 in Paris, focused on patients with clear cell renal cell carcinoma (ccRCC).If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/KURA">KURA shares</a> would hit their highest levels since Jan. 7, 2026.<h2 class="st-heading-2">Strong Response Rates, But Small Sample Size</h2>Kura shared initial results from an ongoing FIT-001 trial testing its investigational therapy, Darlifarnib, in combination with Cabozantinib, a type of target enzyme inhibitor, in kidney cancer patients who had already been treated with Cabozantinib.The treatment showed an objective response rate of 44% and a disease control rate of 94%. Tumor shrinkage was seen in 75% of patients, including those who had previously shown limited response to Cabozantinib.Of the 16 patients receiving treatment over an 8- to 56-week period, six are still receiving therapy at the time of the analysis, the company said.<h2 class="st-heading-2">What Investors Should Watch Next</h2>The treatment also demonstrated a manageable safety profile across different dose levels. The study is testing Darlifarnib at daily doses of 3 mg, 5 mg, or 8 mg, taken in cycles of 7 days on and 7 days off, along with daily Cabozantinib at 60 mg or 40 mg. All patients in the study have previously received immunotherapy.The study is now advancing into Phase 1b to further evaluate the optimal dosing and potential benefits of the regimen.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the run-up to start soon.<stembedurl>https://stocktwits.com/mulc/message/650490176</stembedurl>Another user expects “positive news” from the company’s conference call.<stembedurl>https://stocktwits.com/Georgeson/message/650542576</stembedurl>Year-to-date, the stock has shed around 15%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

The biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer.

Why Did KURA Stock Jump 13% In Pre-Market Today?

Equity

Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital

Lake Street Capital upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday...

Kura Oncology (NASDAQ:KURA) Trading Up 4.8%  - Here's What Happened

Kura Oncology (NASDAQ:KURA) Stock Price Up 4.8% - Should You Buy...

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume  - Time to Buy?

Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume - Should You Buy...

Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Current Price	$9.27
Prev Close	$9.53
Open	$9.49
Dividend Yield	0.00%
50-Day Moving Average	$8.66
Beta	1.05
Avg. Volume	1.53M
PE Ratio	-2.92

52-Week High	$12.49
52-Week Low	$5.45
Market Capitalization	$841.78M
EPS (Annual)	-$3.18
Price to Book	4.68
Revenue Per Employee	$259,546.15

KURA
Kura Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KURA News

KURAKura Oncology Inc